| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Published online before print May 22, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
* Departments of Pharmacology and
Immunology & Rheumatology, Merck Research Laboratories, Rahway, New Jersey
Correspondence: Dr. Jenny H. Xie, R80Y-125, Merck Research Laboratories, P.O. Box 2000, Rahway, NJ 07065. E-mail: Jenny_xie{at}merck.com
Naïve T cells, when activated by specific antigen and cytokines, up-regulate adhesion molecules as well as chemokine receptors on their surface, which allows them to migrate to inflamed tissues. Human studies have shown that CXCR3 is one of the chemokine receptors that is induced during T cell activation. Moreover, CXCR3-positive T cells are enriched at inflammatory sites in patients with autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. In this study, we use a mouse model of inflammation to demonstrate that CXCR3 is required for activated T cell transmigration to inflamed tissue. Using an anti- mCXCR3 antibody, we have shown that in vitro-differentiated T helper (Th) 1 and Th2 cells up-regulated CXCR3 upon stimulation with specific antigen/major histocompatibility complex. However, only Th1 cells, when adoptively transferred to syngeneic recipients, are efficiently recruited to the peritoneum in an adjuvant-induced peritonitis model. Furthermore, the neutralizing anti-mCXCR3 antibody profoundly inhibits the recruitment of Th1 cells to the inflamed peritoneum. Real-time, quantitative reverse transcriptase-polymerase chain reaction analysis demonstrates that the CXCR3 ligands, interferon (IFN)-inducible protein 10 (CXCL10) and IFN-inducible T cell 
chemoattractant (CXCL11), are among the many chemokines induced in the adjuvant-treated peritoneum. The anti-mCXCR3 antibody is also effective in inhibiting a delayed-type hypersensitivity response, which is largely mediated by enhanced trafficking of activated T cells to peripheral inflammatory sites. Collectively, our results suggest that CXCR3 has a critical role in T cell transmigration to sites of inflammation and thus, may serve as a molecular target for anti-inflammatory therapies.
Key Words: Th1/Th2 • chemokines • cell trafficking
This article has been cited by other articles:
|
|
 |
|
  J. Menke, G. C. Zeller, E. Kikawada, T. K. Means, X. R. Huang, H. Y. Lan, B. Lu, J. Farber, A. D. Luster, and V. R. Kelley CXCL9, but not CXCL10, Promotes CXCR3-Dependent Immune-Mediated Kidney Disease J. Am. Soc. Nephrol., June 1, 2008; 19(6): 1177 - 1189. [Full Text] [PDF]
|
|
|
|
 |
|
 K. B. Walsh, M. B. Lodoen, R. A. Edwards, L. L. Lanier, and T. E. Lane Evidence for Differential Roles for NKG2D Receptor Signaling in Innate Host Defense against Coronavirus-Induced Neurological and Liver Disease J. Virol., March 15, 2008; 82(6): 3021 - 3030. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J.A. van Wanrooij, S. C.A. de Jager, T. van Es, P. de Vos, H. L. Birch, D. A. Owen, R. J. Watson, E. A.L. Biessen, G. A. Chapman, T. J.C. van Berkel, et al. CXCR3 Antagonist NBI-74330 Attenuates Atherosclerotic Plaque Formation in LDL Receptor-Deficient Mice Arterioscler. Thromb. Vasc. Biol., February 1, 2008; 28(2): 251 - 257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Mohan and T. B. Issekutz Blockade of Chemokine Receptor CXCR3 Inhibits T Cell Recruitment to Inflamed Joints and Decreases the Severity of Adjuvant Arthritis J. Immunol., December 15, 2007; 179(12): 8463 - 8469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Chakravarty, J. Xu, B. Lu, C. Gerard, J. Flynn, and J. Chan The Chemokine Receptor CXCR3 Attenuates the Control of Chronic Mycobacterium tuberculosis Infection in BALB/c Mice J. Immunol., February 1, 2007; 178(3): 1723 - 1735. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T Ellingsen, N Hornung, B K Moller, J H Poulsen, and K Stengaard-Pedersen Differential effect of methotrexate on the increased CCR2 density on circulating CD4 T lymphocytes and monocytes in active chronic rheumatoid arthritis, with a down regulation only on monocytes in responders Ann Rheum Dis, February 1, 2007; 66(2): 151 - 157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Koch, M. Gaczkowski, G. Sturton, P. Staib, T. Schinkothe, E. Klein, A. Rubbert, K. Bacon, K. Wassermann, and E. Erdmann Modification of surface antigens in blood CD8+ T-lymphocytes in COPD: effects of smoking Eur. Respir. J., January 1, 2007; 29(1): 42 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. N. Stiles, J. L. Hardison, C. S. Schaumburg, L. M. Whitman, and T. E. Lane T Cell Antiviral Effector Function Is Not Dependent on CXCL10 Following Murine Coronavirus Infection J. Immunol., December 15, 2006; 177(12): 8372 - 8380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Tischner, A. Weishaupt, J. v. d. Brandt, N. Muller, N. Beyersdorf, C. W. Ip, K. V. Toyka, T. Hunig, R. Gold, T. Kerkau, et al. Polyclonal expansion of regulatory T cells interferes with effector cell migration in a model of multiple sclerosis Brain, October 1, 2006; 129(10): 2635 - 2647. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Duftner, C Dejaco, W Kullich, A Klauser, C Goldberger, A Falkenbach, and M Schirmer Preferential type 1 chemokine receptors and cytokine production of CD28- T cells in ankylosing spondylitis Ann Rheum Dis, May 1, 2006; 65(5): 647 - 653. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Liu, D. Huang, M. Matsui, T. T. He, T. Hu, J. DeMartino, B. Lu, C. Gerard, and R. M. Ransohoff Severe Disease, Unaltered Leukocyte Migration, and Reduced IFN-{gamma} Production in CXCR3-/- Mice with Experimental Autoimmune Encephalomyelitis J. Immunol., April 1, 2006; 176(7): 4399 - 4409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J.A. van Wanrooij, H. Happe, A. D. Hauer, P. de Vos, T. Imanishi, H. Fujiwara, T. J.C. van Berkel, and J. Kuiper HIV Entry Inhibitor TAK-779 Attenuates Atherogenesis in Low-Density Lipoprotein Receptor-Deficient Mice Arterioscler. Thromb. Vasc. Biol., December 1, 2005; 25(12): 2642 - 2647. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Lord, R. M. Rao, H. Choe, B. M. Sullivan, A. H. Lichtman, F. W. Luscinskas, and L. H. Glimcher T-bet is required for optimal proinflammatory CD4+ T-cell trafficking Blood, November 15, 2005; 106(10): 3432 - 3439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. R. Veillard, S. Steffens, G. Pelli, B. Lu, B. R. Kwak, C. Gerard, I. F. Charo, and F. Mach Differential Influence of Chemokine Receptors CCR2 and CXCR3 in Development of Atherosclerosis In Vivo Circulation, August 9, 2005; 112(6): 870 - 878. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Heise, A. Pahuja, S. C. Hudson, M. S. Mistry, A. L. Putnam, M. M. Gross, P. A. Gottlieb, W. S. Wade, M. Kiankarimi, D. Schwarz, et al. Pharmacological Characterization of CXC Chemokine Receptor 3 Ligands and a Small Molecule Antagonist J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1263 - 1271. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Widney, Y. Hu, A. K. Foreman-Wykert, K. C. Bui, T. T. Nguyen, B. Lu, C. Gerard, J. F. Miller, and J. B. Smith CXCR3 and Its Ligands Participate in the Host Response to Bordetella bronchiseptica Infection of the Mouse Respiratory Tract but Are Not Required for Clearance of Bacteria from the Lung Infect. Immun., January 1, 2005; 73(1): 485 - 493. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Sarween, A. Chodos, C. Raykundalia, M. Khan, A. K. Abbas, and L. S. K. Walker CD4+CD25+ Cells Controlling a Pathogenic CD4 Response Inhibit Cytokine Differentiation, CXCR-3 Expression, and Tissue Invasion J. Immunol., September 1, 2004; 173(5): 2942 - 2951. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Giarratana, G. Penna, S. Amuchastegui, R. Mariani, K. C. Daniel, and L. Adorini A Vitamin D Analog Down-Regulates Proinflammatory Chemokine Production by Pancreatic Islets Inhibiting T Cell Recruitment and Type 1 Diabetes Development J. Immunol., August 15, 2004; 173(4): 2280 - 2287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Proost, S. Verpoest, K. V. de Borne, E. Schutyser, S. Struyf, W. Put, I. Ronsse, B. Grillet, G. Opdenakker, and J. V. Damme Synergistic induction of CXCL9 and CXCL11 by Toll-like receptor ligands and interferon-{gamma} in fibroblasts correlates with elevated levels of CXCR3 ligands in septic arthritis synovial fluids J. Leukoc. Biol., May 1, 2004; 75(5): 777 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Tsunoda, T. E Lane, J. Blackett, and R. S Fujinami Distinct roles for IP-10/C XC L10 in three animal models, Theiler's virus infection, EA E, and MHV infection, for multiple sclerosis: implication of differing roles for IP-10 Multiple Sclerosis, February 1, 2004; 10(1): 26 - 34. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Segerer, B. Banas, M. Wornle, H. Schmid, C. D. Cohen, M. Kretzler, M. Mack, E. Kiss, P. J. Nelson, D. Schlondorff, et al. CXCR3 Is Involved in Tubulointerstitial Injury in Human Glomerulonephritis Am. J. Pathol., February 1, 2004; 164(2): 635 - 649. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
